It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 16:41:31 Source:entertainmentViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Russian theater director and playwright go on trial over a play authorities say justifies terrorism
You may also like
- Company wins court ruling to continue development of Michigan factory serving EV industry
- Teenage golfer Ji wins first pro title in Tianjin
- Teixeira scores late as Shanghai derby ends all square
- College protests: Anti
- Kevin Pillar gets 1,000th career hit in Angels' win at Texas
- 'Hideous' newbuild house with a 'kitchen floor' outside is slammed for crucial design flaw
- China dominates Thomas & Uber Cup group opener
- Keir Starmer vows to protect pensions triple lock if Labour is victorious at the next election
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East